港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

496.720

-5.792-1.15%

漲家數：6

跌家數：25

平家數：2

市盈率：- -

高：507.303

開：502.573

低：495.158

收：502.512

成交量：8,175.03萬

成交額：18.06億

市值：3,152.73億

流通市值：2,806.09億

資料載入中...

總覽新聞資訊

港股開盤｜港股低開；醫藥股逆市走強；聯想漲逾2%

這家「最會賺錢的創新藥第一股」，貝達藥業赴港IPO，未來懸念重重……

中報之後再看心瑋醫療-B(6609.HK)：業績高增背後的神經介入邏輯

兩起涉中醫藥網絡違規營銷宣傳問題被依法查處；先聲再明與羅氏達成總金額超15億美元合作丨醫藥早參

每日经济新闻

歐康維視生物：地塞米松眼內懸濁液上市申請獲國家藥監局受理

諾華製藥（NVS）漲6% 在BTK抑制劑賽道迎來重要突破

美股異動 | 諾華製藥升逾5%，MS口服藥後期試驗告捷

諾華製藥(NVS)股票9月1日盤中上漲6.54%：真相來了

TradingKey中文

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BK1574/news?page=18"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.744174","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":166.585651,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:18,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1144703788","title":"港股開盤｜港股低開；醫藥股逆市走強；聯想漲逾2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144703788","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144703788?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:23","pubTimestamp":1788312190,"startTime":"0","endTime":"0","summary":"核心科网股表现分化：受AI服务器需求利好刺激，联想集团逆势上涨逾2%，其余多数龙头回调0.2%–1%不等。盘面异动方面，数据中心概念新意网高开近7%领跑；医药股获资金青睐，先声药业、云顶新耀等延续强势；黄金股则受金价走弱影响集体下挫，万物云大跌近7%拖累物业管理板块。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4585","LU0672654166.SGD","159938","LU0048580855.USD","03441","LU1235295612.USD","LU0572939691.SGD","LU1046422090.SGD","LU0052756011.USD","LU1267930227.SGD","LU0972618739.USD","LU2242644610.SGD","BK1607","LU0128522157.USD","BK4588","BK1515","IE0034224299.USD","LU0264606111.USD","IE00B0JY6N72.USD","LU0128525689.USD","LU1785774172.SGD","HK0000306701.USD","LU0791590937.USD","HK0000320264.USD","09939","LU0049112450.USD","BK1161","LU0572940350.SGD","LU0862451837.USD","LU0890818403.SGD","TCHI","LU0862451753.SGD","LU0029875118.USD","IE0003895053.USD","LU1366334578.USD","BK1526","00992","LU0543330483.HKD","80992","VXUS","LU0310800965.SGD","LNVGY","LU0791591158.USD","LU0370786039.SGD","BK1193","IE0032431581.USD","HK0000320223.HKD","HK0000306685.HKD","LU0320764755.SGD","LU1366334651.USD","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867024","title":"這家「最會賺錢的創新藥第一股」，貝達藥業赴港IPO，未來懸念重重……","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867024","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664867024?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 08:53","pubTimestamp":1788310380,"startTime":"0","endTime":"0","summary":"老药的余晖埃克替尼之于贝达药业，是起点，也是命脉。仿制药上市后几乎必然以低价渗透市场，一旦竞争充分，埃克替尼或将被迫卷入国家或地区集中带量采购，面临进一步的降价压力。招股书承认，协议项下合计人民币1.8亿元的若干监管里程碑付款已被触发，并成为公司的应付款项。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-02/doc-iniqkvce1333036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","300558","FRHC","MEDX","06978","BK0239","159992","BK4127","KCE","REDS","LNGR","IPOS","BK1161","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664692867","title":"中報之後再看心瑋醫療-B(6609.HK)：業績高增背後的神經介入邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664692867","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664692867?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 08:48","pubTimestamp":1788310086,"startTime":"0","endTime":"0","summary":"期内经调整净利润约7036.7万元，同比增幅达105.9%，远超收入增速","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6454556","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06609","BK1587","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664455864","title":"兩起涉中醫藥網絡違規營銷宣傳問題被依法查處；先聲再明與羅氏達成總金額超15億美元合作丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2664455864","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664455864?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 07:00","pubTimestamp":1788303631,"startTime":"0","endTime":"0","summary":"丨2026年9月2日星期三丨NO.1国家中医药管理局会同有关部门依法查处两起涉中医药网络违规营销宣传问题国家中医药管理局通报称，近期，在中医医疗违法违规行为专项治理工作中，国家中医药管理局会同有关部门，依法查处了两起涉中医药网络违规营销宣传问题。一是“‘香港大药房’网店违规营销案”。多家以“香港大药房”名义开设的网店销售“透骨膏”“无湿丸”等产品，在直播营销中涉嫌虚假宣传。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023861922880.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023861922880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1574","159938","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198144529","title":"歐康維視生物：地塞米松眼內懸濁液上市申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1198144529","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198144529?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 00:09","pubTimestamp":1788278991,"startTime":"0","endTime":"0","summary":"路透9月1日消息——欧康维视生物（股票代码：1477.HK）今日宣布，其地塞米松眼内悬浊液的新药上市申请，已正式获得中国国家药品监督管理局（NMPA）受理，该申请被归类为4类化学药品。此次受理标志着公司在眼科治疗领域的又一重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850928","title":"諾華製藥（NVS）漲6% 在BTK抑制劑賽道迎來重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850928","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850928?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:18","pubTimestamp":1788275914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药 早盘股价扬升，最新涨6%，报161.2美元，成交额3.2亿美元。诺华周二公布，对比对照药物特立氟胺，瑞米布替尼可降低患者疾病复发率，减少脑部病灶数量，试验中未观察到肝脏相关安全风险。该药有望成为诺华重磅产品Kesimpta的后续迭代品种，同时印证BTK抑制剂在抑制异常免疫反应方面的治疗潜力。诺华计划向全球监管机构提交瑞米布替尼治疗多发性硬化症的上市申请，完整临床数据将于今年晚些时候在多伦多医学会议对外披露。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305587","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU0320765489.SGD","LU0211331839.USD","IE0009355771.USD","BK1191","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK1574","NVS","LU0208291251.USD","BK4585","BK4532","IE00BJT1NW94.SGD","BK4588","PPH","01477","IE0002141913.USD","BK4007","BK4578","IE00BJJMRZ35.SGD","MEDX","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664016854","title":"美股異動 | 諾華製藥升逾5%，MS口服藥後期試驗告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664016854","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664016854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:35","pubTimestamp":1788273301,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，诺华制药涨逾5%，报160.82美元。消息面上，诺华表示，试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。此前，赛诺菲和默克公司的类似药物在后期试验中未能在复发率指标上优于特立氟胺。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490652.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺华制药MS口服药后期试验告捷","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00BFTCPJ56.SGD","BK4532","IE00B4R5TH58.HKD","NVS","BK1191","IE0002141913.USD","PPH","LU0211331839.USD","BK4007","LU0320765489.SGD","BK4578","IE00BJT1NW94.SGD","MEDX","LU0208291251.USD","BK1574","LU0070302665.USD","IE00BJJMRZ35.SGD","BK4585","IE00B2B36J28.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664524478","title":"諾華製藥(NVS)股票9月1日盤中上漲6.54%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2664524478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664524478?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:16","pubTimestamp":1788272176,"startTime":"0","endTime":"0","summary":"• Remibrutinib 在三期多发性硬化症试验中取得成功，展现出临床优效性。\n• 在三名患者死亡后，诺华暂停了八项早期 CAR-T 试验。\n• 该公司报告年收入为 563.3 亿美元，净利润为 139.8 亿美元。","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262144173-market-movers-nvs-20260901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","BK1574","IE00BJJMRZ35.SGD","NVS","01477","BK4007","BK4588","LU0211331839.USD","IE00BFTCPJ56.SGD","MEDX","PPH","BK4578","BK1191","LU0070302665.USD","BK4532","IE0009355771.USD","IE0002141913.USD","BK4585","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":18,"totalSize":348,"code":"91000000","status":"200"}]}}